image
Healthcare - Biotechnology - NASDAQ - US
$ 0.78
-6.33 %
$ 2.09 M
Market Cap
-0.54
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 22, 2025.

The intrinsic value of one LIXT stock under the worst case scenario is HIDDEN Compared to the current market price of 0.78 USD, Lixte Biotechnology Holdings, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 22, 2025.

The intrinsic value of one LIXT stock under the base case scenario is HIDDEN Compared to the current market price of 0.78 USD, Lixte Biotechnology Holdings, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 22, 2025.

The intrinsic value of one LIXT stock under the best case scenario is HIDDEN Compared to the current market price of 0.78 USD, Lixte Biotechnology Holdings, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart LIXT

image
$3.0$3.0$2.5$2.5$2.0$2.0$1.5$1.5$1.0$1.0$0.5$0.5Jan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 Jun
FINANCIALS
0 REVENUE
0.00%
-3.57 M OPERATING INCOME
29.80%
-3.59 M NET INCOME
29.51%
-3.16 M OPERATING CASH FLOW
26.29%
0 INVESTING CASH FLOW
0.00%
0 FINANCING CASH FLOW
0.00%
0 REVENUE
0.00%
-707 K OPERATING INCOME
-15.32%
-710 K NET INCOME
-14.87%
-568 K OPERATING CASH FLOW
5.04%
914 K INVESTING CASH FLOW
0.00%
914 K FINANCING CASH FLOW
0.00%
Balance Sheet Lixte Biotechnology Holdings, Inc.
image
Current Assets 1.04 M
Cash & Short-Term Investments 1.04 M
Receivables 0
Other Current Assets 0
Non-Current Assets 0
Long-Term Investments 0
PP&E 0
Other Non-Current Assets 0
100.00 %Total Assets$1.0m
Current Liabilities 318 K
Accounts Payable 0
Short-Term Debt 0
Other Current Liabilities 318 K
Non-Current Liabilities 0
Long-Term Debt 0
Other Non-Current Liabilities 0
100.00 %Total Liabilities$318.3k
EFFICIENCY
Earnings Waterfall Lixte Biotechnology Holdings, Inc.
image
Revenue 0
Cost Of Revenue 0
Gross Profit 0
Operating Expenses 3.57 M
Operating Income -3.57 M
Other Expenses 13 K
Net Income -3.59 M
00(500k)(500k)(1m)(1m)(1m)(1m)(2m)(2m)(2m)(2m)(3m)(3m)(3m)(3m)(4m)(4m)000(4m)(4m)(13k)(4m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-433.50% ROE
-433.50%
-313.05% ROA
-313.05%
-495.76% ROIC
-495.76%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Lixte Biotechnology Holdings, Inc.
image
00(500k)(500k)(1m)(1m)(1m)(1m)(2m)(2m)(2m)(2m)(3m)(3m)(3m)(3m)(4m)(4m)(4m)(4m)(5m)(5m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -3.59 M
Depreciation & Amortization 30 K
Capital Expenditures 0
Stock-Based Compensation 418 K
Change in Working Capital 3.01 K
Others 421 K
Free Cash Flow -3.16 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Lixte Biotechnology Holdings, Inc.
image
LIXT has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 10
6. Ownership
Insider Ownership Lixte Biotechnology Holdings, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100 Pre-Clinical Study in Collaboration with Netherlands Cancer Institute is in addition to LIXTE's Ongoing Clinical Trials for Ovarian and Colorectal Cancers globenewswire.com - 3 months ago
LIXTE Biotechnology Provides Update On Progress with Proprietary Compound, LB-100, to Treat Ovarian and Colorectal Cancer -Started Two New Clinical Trials,  Collaborating with MD Anderson and The Netherlands Cancer Institute for Treatment of Ovarian and Colorectal Cancer- globenewswire.com - 3 months ago
LIXTE Adds Northwestern University's Lurie Cancer Center as Second Site in Ongoing Clinical Trial for Ovarian Clear Cell Cancer -- Lurie Cancer Center Completes Dosing of First Patient with LIXTE's LB-100  in Combination with GSK's Immunotherapy Dostarlimab -- PASADENA, CALIF., Feb. 25, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) ( Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced it has added the Robert H. Lurie Comprehensive Cancer Center (Lurie Cancer Center) of Northwestern University as a second site in a clinical trial combining the Company's proprietary compound LB-100 with GSK's Dostarlimab to treat ovarian clear cell cancer. globenewswire.com - 4 months ago
LIXTE Biotechnology Announces Closing of $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules PASADENA, CALIF., Feb. 13, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of an aggregate of 434,784 shares of the Company's common stock at a purchase price of $2.415 per share. In addition, in a concurrent private placement, the Company issued unregistered warrants to purchase up to an aggregate of 434,784 shares of common stock. The warrants have an exercise price of $2.29 per share and are exercisable for five years from the date of issuance. globenewswire.com - 4 months ago
LIXTE Biotechnology Announces $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules PASADENA, CALIF., Feb. 11, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 434,784 shares of its common stock at a purchase price of $2.415 per share, in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered warrants to purchase up to an aggregate of 434,784 shares of common stock. The warrants will have an exercise price of $2.29 per share and will be exercisable for five years from the date of issuance. The closing of the offering is expected to occur on or about February 12, 2025, subject to the satisfaction of customary closing conditions. globenewswire.com - 4 months ago
LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement PASADENA, CALIF., Feb. 10, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the “Company”) ( Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced that it has filed a request for withdrawal with the Securities and Exchange Commission (the “SEC”) of the Company's Registration Statement on Form S-1 (No. 333-282781), as amended, originally filed on October 23, 2024 (the “Registration Statement”), as the Company no longer intends to pursue a public offering under the Registration Statement at this time. The Registration Statement has not been declared effective by the SEC, and no securities have been sold in connection with the offering described in the Registration Statement. globenewswire.com - 4 months ago
LIXTE Receives U.S. Patent Issue Notification for Immune Oncology Patent Covers Combining LIXTE's LB-100 with Various Innovative Cancer Immunotherapies PASADENA, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. globenewswire.com - 9 months ago
First Patient Dosed with LIXTE's LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company PASADENA, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) (“LIXTE” or the “Company”), today announced the dosing of the first patient in a new clinical trial in collaboration with the Netherlands Cancer Institute (NKI) and supported by F. Hoffmann-La Roche Ltd. (“Roche”) for treatment of unresponsive (MSI Low) metastatic colorectal cancer. globenewswire.com - 10 months ago
LIXTE Biotechnology Provides Update On Recent Activities and Developments -Collaboration with NKI and Funding Support for New Colorectal Cancer Clinical Trial  by Major Pharma Company- globenewswire.com - 10 months ago
LIXTE Biotechnology Holdings to Present at Two Investor Conferences -Company to Present August 20 at Investor Summit Summer 2024 Virtual Conference; and September 9-11 at H.C. Wainwright 26 th Annual Global Investment Conference- globenewswire.com - 10 months ago
Lixte Biotechnology Holdings, Inc. to Present at August 20th Virtual Investor Summit Microcap Event NEW YORK, NY / ACCESSWIRE / August 14, 2024 / Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. The company will be available for 1-on-1 meetings throughout the day in addition to their presentation. accesswire.com - 10 months ago
LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial Clinical trial to test recent findings that show LIXTE's lead clinical compound, LB-100, increases recognition of colon cancer cells by the immune system globenewswire.com - 1 year ago
8. Profile Summary

Lixte Biotechnology Holdings, Inc. LIXT

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 2.09 M
Dividend Yield 0.00%
Description Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures for the treatment of cancers, and vascular and metabolic diseases; and LB-200 series to treat chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, as well as Netherlands Cancer Institute and Oncode Institute. The company was founded in 2005 and is based in Pasadena, California.
Contact 680 East Colorado Boulevard, Pasadena, CA, 91101 https://lixte.com
IPO Date Oct. 25, 2007
Employees 2
Officers Mr. Robert Neal Weingarten Chief Financial Officer, Vice President & Secretary Mr. Johannes Henricus Matthias Schellens M.D., Ph.D. Consultant & Chief Medical Officer Mr. Bastiaan van der Baan M.Sc. President, Chief Executive Officer & Chairman of the Board of Directors